An Observational Clinical Study to Collect Photographic Data of Wounds With Hypergranulation to Aid Development of a Hypergranulation Clinical Endpoint and Assessment Tool, And Generate Participant Reported Data to Inform Trial Design

Last updated: January 12, 2026
Sponsor: Ennogen Healthcare Limited
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pressure Ulcers

Treatment

Hypergranulation Tool Proforma

Device to take 2D images of wounds to allow for construction of a 3D image of the wound to assess degree of hypergranulation

Clinical Study ID

NCT07334717
EHCI HG 04-01
365713
  • Ages 2-85
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Hypergranulation (HG) is well documented and a known barrier to wound healing. Accurate clinical assessment of wounds is crucial in managing HG and evaluating treatment response. Currently there is no standardised assessment for healthcare professionals to assess the severity of HG. Through a modified Delphi process involving wound care clinical experts, a prototype Hypergranulation Tool has been developed to be used in clinical practice. The Hypergranulation Tool allows assessors to grade HG within wounds as mild, moderate and severe, based on 5 separate parameters. A prospective multi-site observational study based in the United Kingdom of 80-100 adult and paediatric patients with HG within venous leg ulcers (VLU) or complex surgical wounds (CSW) will allow performance testing of the Hypergranulation Tool. Study nurses will assess wounds with the Hypergranulation Tool across 2-4 clinic visits. Data from the use of the tool will be compared with quantitative 3D analysis of the wounds, patient reported outcome and patient interview data, to help determine the validity of the Hypergranulation Tool in the clinical setting. Results from the Observational Study will inform design changes to the Hyergranulation Tool as well as the design of future HG intervention trials.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Male or female participants between 2 to 85 years of age (both inclusive).

  • Willing and able to provide written informed consent or assent (as applicable) as evidenced by signature on the participant's consent/assent form. In case if the child is providing assent, a caregiver or LAR must sign an informed consent.

  • A chronic HG wound which can be:

  • a VLU unhealed for a minimum of 6 weeks, but no longer than 24 weeks

  • an unhealed surgical wound that has been unhealed for at least 2 weeks but no longer than 24 weeks

  • a device entering the skin (eg, gastrostomy, suprapubic catheter, tracheostomy etc) that exhibits HG.

  • A degree of HG that is estimated to be raised at least 2 mm above the natural skin level, or above the base of the wound and an area of HG extending at least 10 mm in its longest length.

  • For VLU and surgical wounds, the wound should not have been healed by at least 25% area or length.

  • Have good general health as defined by:

  • medically fit enough to complete the study assessments

  • free of any other systemic condition that in the opinion of the Study Investigator may have an impact on the safety of the participant.

  • Be willing and able to attend all scheduled clinical assessments, (adults or caregiver)

  • able to communicate well with the Study Investigator and willing and able to comply with the expectations of the study.

  • This includes gastrostomy; suprapubic catheters, tracheostomy, other tube/catheter skin entry or exit sites, abdominal surgical wound, pilonidal sinus surgical site, split-skin donor site, plastic surgery sites, healing burn sites, peri-anal surgical wounds, gastrointestinal stoma, other.

Exclusion Criteria

  • Unable to provide informed consent or assent

  • Unable to complete the scheduled study treatments and assessments

  • Have been previously recruited into this study

  • Participants who are < 2 years or >85 years of age

Study Design

Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Hypergranulation Tool Proforma
Phase:
Study Start date:
February 01, 2026
Estimated Completion Date:
August 31, 2026

Connect with a study center

  • EMS Healthcare

    Ellesmere Port 2650096, Cheshire CH65 4LE
    United Kingdom

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.